Literature DB >> 33283961

Aplasia cutis congenita in a CDC42-related developmental phenotype.

Franziska Schnabel1, Susanne B Kamphausen2, Rudolf Funke3, Silke Kaulfuß1, Bernd Wollnik1,4, Martin Zenker2.   

Abstract

Cell division cycle 42 (CDC42) is a small Rho GTPase, which serves as a fundamental intracellular signal node regulating actin cytoskeletal dynamics and several other integral cellular processes. CDC42-associated disorders encompass a broad clinical spectrum including Takenouchi-Kosaki syndrome, autoinflammatory syndromes and neurodevelopmental phenotypes mimicking RASopathies. Dysregulation of CDC42 signaling by genetic defects in either DOCK6 or ARHGAP31 is also considered to play a role in the pathogenesis of Adams-Oliver syndrome (AOS). Here, we report a mother and her child carrying the previously reported pathogenic CDC42 variant c.511G>A (p.Glu171Lys). Both affected individuals presented with short stature, distinctive craniofacial features, pectus deformity as well as heart and eye anomalies, similar to the recently described Noonan syndrome-like phenotype associated with this variant. Remarkably, one of the patients additionally exhibited aplasia cutis congenita of the scalp. Multi-gene panel sequencing of the known AOS-causative genes and whole exome sequencing revealed no second pathogenic variant in any disease-associated gene explaining the aplasia cutis phenotype in our patient. This observation further expands the phenotypic spectrum of CDC42-associated disorders and underscores the role of CDC42 dysregulation in the pathogenesis of aplasia cutis congenita.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  CDC42; Noonan syndrome-like disorder; aplasia cutis congenita

Mesh:

Substances:

Year:  2020        PMID: 33283961     DOI: 10.1002/ajmg.a.62009

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  2 in total

1.  The seventh international RASopathies symposium: Pathways to a cure-expanding knowledge, enhancing research, and therapeutic discovery.

Authors:  Maria I Kontaridis; Amy E Roberts; Lisa Schill; Lisa Schoyer; Beth Stronach; Gregor Andelfinger; Yoko Aoki; Marni E Axelrad; Annette Bakker; Anton M Bennett; Alberto Broniscer; Pau Castel; Caitlin A Chang; Lukas Cyganek; Tirtha K Das; Jeroen den Hertog; Emilia Galperin; Shruti Garg; Bruce D Gelb; Kristiana Gordon; Tamar Green; Karen W Gripp; Maxim Itkin; Maija Kiuru; Bruce R Korf; Jeff R Livingstone; Alejandro López-Juárez; Pilar L Magoulas; Sahar Mansour; Theresa Milner; Elisabeth Parker; Elizabeth I Pierpont; Kevin Plouffe; Katherine A Rauen; Suma P Shankar; Shane B Smith; David A Stevenson; Marco Tartaglia; Richard Van; Morgan E Wagner; Stephanie M Ware; Martin Zenker
Journal:  Am J Med Genet A       Date:  2022-03-09       Impact factor: 2.578

2.  Synergistic effects of rare variants of ARHGAP31 and FBLN1 in vitro in terminal transverse limb defects.

Authors:  Hong Tian; Fan Chu; Yingjie Li; Mengmeng Xu; Wenjiao Li; Chuanzhou Li
Journal:  Front Genet       Date:  2022-09-13       Impact factor: 4.772

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.